Mathematical models of the fate of lymphoma B cells after antigen receptor ligation with specific antibodies

Journal of Theoretical Biology

Volumn 240, Issue 1, 2006, Pages 54-71

  Alarcón, Tomás ^a   Marches, Radu ^b   Page, Karen M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Cell cycle; Dormancy; Lymphoma; Myc; Quiescence

Indexed keywords

B LYMPHOCYTE RECEPTOR; CASPASE; CYCLIN DEPENDENT KINASE INHIBITOR 1; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; LYMPHOCYTE ANTIGEN RECEPTOR; MYC PROTEIN; PROTEIN P21; RECEPTOR ANTIBODY;

ANTIBODY; ANTIGEN; BIFURCATION; MODEL; SENSITIVITY ANALYSIS;

ANIMAL CELL; ANTIBODY SPECIFICITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CELL CYCLE; CELL FATE; DAUDI CELL; DORMANCY; ENZYME ACTIVITY; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY ANALYSIS;

APOPTOSIS; CASPASES; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; IMMUNOGLOBULIN M; LYMPHOMA, B-CELL; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; RECEPTORS, ANTIGEN, B-CELL;

ANIMALIA;

EID: 33646071798     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2005.08.028     Document Type: Article

References (34)

1. Abram C.L., and Courtneidge S.A. Src family tyrosine kinases and growth factor signalling. Exp. Cell Res. 254 (2000) 1-13
2. Alarcón T., Byrne H.M., and Maini P.K. A mathematical model of the effects of hypoxia on the cell-cycle of normal and cancer cells. J. Theor. Biol. 229 (2004) 395-411
3. Alberts B., Bray D., Lewis J., Roberts K., and Watson J.D. Molecular Biology of the Cell (1994), Garland Publishing, New York, NY, USA
4. Bloom J., and Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin. Can. Biol. 13 (2003) 41-47
5. Caspar C.B., Levy S., and Levy R. Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations. Blood 90 (1997) 3699-3706
6. Kip 1 levels. J. Immunol. 172 (2004) 5522-5527
7. Chiarello M., Marinissen M.J., and Gutkind J.S. Regulation of c-myc expression by PDGF through Rho GTPases. Nat. Cell Biol. 3 (2001) 580-586
8. Coller H.A., Grandori C., Tamayo P., Colbert T., Lander E.S., Eisenman R.N., and Golub T.R. Expression analysis with oligonucleotide microarrays reveals that Myc regulates genes involved in growth, cell-cycle, signalling and adhesion. Proc. Natl Acad. Sci. USA 97 (2000) 3260-3265
9. Cory S., Huang D.C.S., and Adams J.M. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22 (2003) 8590-8607
10. Dang C.V., Resar L.M.S., Emison E., Kim S., Li Q., Preston J.E., Wonsey D., and Zeller K. Function of the c-Myc oncogenic transcription factor. Exp. Cell Res. 253 (1999) 63-77
11. Degterev A., Boyce M., and Yuan J. A decade of caspases. Oncogene 22 (2003) 8543-8567
12. Erlanson M., Lidth J., Zackrisson B., Landberg G., and Ross G. Cell kinetic analysis of Non-Hodgkin lymphomas using in vivo iodeoxyuridine incorporation and flow cytometry. Hematol. Oncol. 13 (1995) 207-217
13. Evan G.I., and Vouden K.H. Proliferation, cell cycle and apoptosis in cancer. Nature 411 (2001) 342-348
14. 1 growth arrest of murine B-cell lymphomas. Mol. Biol. Cell. 7 (1996) 553-564
15. WAF 1 / CIP 1 promoter and interacts with Sp1/Sp3
16. Kip 1 through overaction of Raf-1 and the MEK/ERK module in proliferating human choroidal melanoma cells. Oncogene 22 (2003) 8813-8822
17. Marches R., Racila E., Tucker T.F., Picker L., Mognini P., Hseuh R., Vitetta E.S., Scheuerman R.H., and Uhr J.W. Tumour dormancy and cell signalling. III. Role of hypercrosslinking of IgM and CD40 on the induction of cell cycle arrest and apoptosis in B lymphoma cells. Ther. Immunol. 2 (1995) 125-136
18. Marches R., Scheuerman R.H., and Uhr J.W. Cancer dormancy: role of cyclin-dependent kinases inhibitors in induction of cell-cycle arrest mediated via membrane IgM. Cancer Res. 58 (1998) 691-697
19. waf 1 initiated by membrane IgM engagement increases survival of B lymphoma cells. Proc. Natl Acad. Sci. USA 96 (1999) 8711-8715
20. Meeker T., Lowder J., Cleary M.L., Stewart S., Warnker R., Sklar J., and Levy R. Emergence of idiotype variants in a monoclonal B-cell lymphoma with anti-idiotype antibodies. N. Engl. J. Med. 312 (1985) 1658-1665
21. Nishioka W.K., and Welsh R.M. Susceptibility to cytotoxic T lymphocyte-induced apoptosis is a function of the proliferative status of the target. J. Exp. Med. 179 (1994) 769-774
22. Novak B., and Tyson J.J. A model for restriction point control of the mammalian cell cycle. J. Theor. Biol. 230 (2004) 563-579
23. Padmanabhan J., Park D.S., Greene L.A., and Shelanski M.L. Role of cell cycle regulatory proteins in cerebral granule neuron apoptosis. J. Neurosci. 19 (1999) 8747-8756
24. Page K.M., and Uhr J. Mathematical models of cancer dormancy. Leuk. Lymphoma 46 (2004) 313-327
25. Press W.H., Flanery B.P., Teukolski S.A., and Vetterling W.T. Numerical Recipes in C: The Art of Scientific Computing (1992), Cambridge University Press, New York, NY, USA
26. Qu Z., Weiss J.N., and MacLellan W.R. Coordination of cell growth and cell division: a mathematical modelling study. J. Cell Sci. 117 (2004) 4199-4207
27. Racila E., Scheuermann R.H., Picker L.J., Yefenof E., Tucker T., Chang W., Marches R., Street N.E., Vitetta E.S., and Uhr J.W. Tumour dormancy and cell signalling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice. J. Exp. Med. 181 (1995) 1539-1550
28. Raff M. Cell suicide for beginners. Nature 396 (1998) 119-122
29. 2 + signalling and volume regulation in proliferating and quiescent cells from multicellular spheroids. J. Cell. Physiol. 175 (1998) 129-140
30. Cip 1 CDK inhibitor influences the outcome of the p53 response to DNA damage. Nature 419 (2002) 729-734
31. Tyson J.J., and Novak B. Regulation of the eukaryotic cell-cycle: molecular antagonism, hysteresis, and irreversible transitions. J. Theor. Biol. 210 (2001) 249-263
32. Uhr J.W., Scheuermann R.H., Street N.E., and Vitetta E.S. Cancer dormancy: opportunities for new therapeutic approaches. Nat. Med. 3 (1997) 505-509
33. Varma A., Morbidelli M., and Wu H. Parametric Sensitivity in Chemical Systems (1999), Cambridge University Press, New York, NY, USA
34. Vitetta E.S., and Uhr J.W. Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy. Cancer Res. 54 (1994) 5301-5309